Loading
A phase 3 trial of Abemaciclib, Erlotinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer is a phase 3 interventional study registered as NCT02152631 by Eli Lilly and Company, with 453 participants enrolled, started 2014-10-03 and due to reach its primary completion in 2017-09-15. Interventions recorded: Abemaciclib, Erlotinib. Conditions listed: Non Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2018; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
453 enrolled.
95% CI 6.5 to 8.8; Figures from the ClinicalTrials.gov results section (first posted 2018-12-12), not from a publication · 95% CI 6.4 to 9.5
Source95% CI 2.8 to 3.8; Figures from the ClinicalTrials.gov results section (first posted 2018-12-12), not from a publication · 95% CI 1.9 to 2.0
Source95% CI 5.5 to 12.3; Figures from the ClinicalTrials.gov results section (first posted 2018-12-12), not from a publication · 95% CI 0.4 to 5.1
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS)primary | Abemaciclib | 270 | 7.4 months | 0.968 (0.768 to 1.219) | 0.771 | link |
| Erlotinib | 183 | 7.8 months | ||||
| Progression Free Survival (PFS) | Abemaciclib | 270 | 3.6 months | 0.583 (0.47 to 0.723) | <0.000001 | link |
| Erlotinib | 183 | 1.9 months | ||||
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | Abemaciclib | 270 | 8.9% | - | 0.010 | link |
| Erlotinib | 183 | 2.7% |
Shares Erlotinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.
Shares Abemaciclib, CDK4/6 inhibitors, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors.